The Relationship Between Pulmonary Function and Dyspnea in Obstructive Lung Disease

Wolkove, Norman; Dajczman, Esther; Colacone, Antoinette; Kreisman, Harvey

doi:10.1378/chest.96.6.1247

Cited by 165 publications

(89 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Modified Borg's scale Modified Borg's scale is a 12-point numerical plus verbal scale that is easy to administer, is reproducible and has been found to correlate with physiological parameters of lung disease in exercise trials (Wolkove et al, 1989;Mador et al, 1995).…”

Section: Methodsmentioning

confidence: 99%

Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale

et al. 2000

View full text Add to dashboard Cite

Summary Dyspnoea is one of the most frequent and refractory symptoms in cancer patients. Lack of an appropriate assessment tool for dyspnoea seems to disturb establishment of management strategy. The purpose of this study was to develop and validate a brief self-rating scale to assess the multidimensional nature of dyspnoea in cancer patients. We developed a 12-item scale, the Cancer Dyspnoea Scale (CDS), composed of three factors (sense of effort/sense of anxiety/sense of discomfort), by using factor analysis. One hundred and sixty-six patients with advanced or recurrent lung cancer participated in the validation phase. The CDS showed good feasibility (average time required to complete it was 140 s). Construct validity, confirmed by repeating factor analysis, was good. Convergent validity, confirmed by a relation to Visual Analogue Scale of dyspnoea and modified Borg's scale, was also good (average: r = 0.57 and 0.52, respectively, and both P < 0.001). The CDS had good internal consistency (average Cronbach's alpha = 0.86) and stability (average test-retest reliability r = 0.66, P < 0.005). The present study demonstrated that the CDS is a brief, valid and feasible scale for assessing the multidimensional nature of dyspnoea in cancer patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale

et al. 2000

View full text Add to dashboard Cite

show abstract

“…In COPD patients, post-bronchodilator FEV1 is poorly correlated with patient-centred outcomes, such as dyspnoea, exercise performance and HRQoL at baseline or after pharmacological interventions [26][27][28][29][30][31]. However, FEV1 has the advantage of being the most repeatable lung function parameter and one that measures changes in both obstructive and restrictive types of lung disease [7].…”

Section: Lung Functionmentioning

confidence: 99%

Outcomes for COPD pharmacological trials: from lung function to biomarkers

Cazzola¹,

MacNee²,

Martínez³

et al. 2008

Eur Respir J

751

566

View full text Add to dashboard Cite

The American Thoracic Society/European Respiratory Society jointly created a Task Force on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations.

show abstract

“…A study done by Wolkove N et al [11] on 93 patients with obstructive lung diseases included the measurement of breathlessness at rest using Borg Scale Dyspneic Index (BSDI) concluded that dyspnea is poorly correlated with results of routine spirometry in patients with obstructive lung diseases and suggested the use of dyspnea ratings may yield about bronchodilator responsiveness not appreciated by spirometry alone. Delclaux C et al [12] studied 49 patients of sickle cell disease and made them underwent direct evaluations (Borg scale evaluation during a six minutes walk test) and indirect evaluations(MMRC dyspnoea score ) for their dyspnoea.…”

Section: Discussionmentioning

confidence: 99%

Profile of Descriptive Parameters of Pulmonary Function in Patients with Dyspnea

Ningshen¹,

Kanan²,

Singh³

et al. 2014

IOSRJDMS

View full text Add to dashboard Cite

The Relationship Between Pulmonary Function and Dyspnea in Obstructive Lung Disease

Cited by 165 publications

References 15 publications

Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale

Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale

Outcomes for COPD pharmacological trials: from lung function to biomarkers

Profile of Descriptive Parameters of Pulmonary Function in Patients with Dyspnea

Contact Info

Product

Resources

About